These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 27770217)
1. Partial Adenosine A1 Agonist in Heart Failure. Dinh W; Albrecht-Küpper B; Gheorghiade M; Voors AA; van der Laan M; Sabbah HN Handb Exp Pharmacol; 2017; 243():177-203. PubMed ID: 27770217 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. Voors AA; Bax JJ; Hernandez AF; Wirtz AB; Pap AF; Ferreira AC; Senni M; van der Laan M; Butler J; Eur J Heart Fail; 2019 Nov; 21(11):1426-1433. PubMed ID: 31523892 [TBL] [Abstract][Full Text] [Related]
3. Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A Meibom D; Albrecht-Küpper B; Diedrichs N; Hübsch W; Kast R; Krämer T; Krenz U; Lerchen HG; Mittendorf J; Nell PG; Süssmeier F; Vakalopoulos A; Zimmermann K ChemMedChem; 2017 May; 12(10):728-737. PubMed ID: 28488817 [TBL] [Abstract][Full Text] [Related]
4. Capadenoson, a clinically trialed partial adenosine A Baltos JA; Vecchio EA; Harris MA; Qin CX; Ritchie RH; Christopoulos A; White PJ; May LT Biochem Pharmacol; 2017 Jul; 135():79-89. PubMed ID: 28344125 [TBL] [Abstract][Full Text] [Related]
5. Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. Voors AA; Düngen HD; Senni M; Nodari S; Agostoni P; Ponikowski P; Bax JJ; Butler J; Kim RJ; Dorhout B; Dinh W; Gheorghiade M J Clin Pharmacol; 2017 Apr; 57(4):440-451. PubMed ID: 27624622 [TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. Voors AA; Shah SJ; Bax JJ; Butler J; Gheorghiade M; Hernandez AF; Kitzman DW; McMurray JJV; Wirtz AB; Lanius V; van der Laan M; Solomon SD Eur J Heart Fail; 2018 Nov; 20(11):1601-1610. PubMed ID: 30225882 [TBL] [Abstract][Full Text] [Related]
9. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Sabbah HN; Gupta RC; Kohli S; Wang M; Rastogi S; Zhang K; Zimmermann K; Diedrichs N; Albrecht-Küpper BE Circ Heart Fail; 2013 May; 6(3):563-71. PubMed ID: 23564604 [TBL] [Abstract][Full Text] [Related]
10. The effect of two selective A Cooper SL; March J; Sabbatini AR; Hill SJ; Jörg M; Scammells PJ; Woolard J Br J Pharmacol; 2020 Jan; 177(2):346-359. PubMed ID: 31596949 [TBL] [Abstract][Full Text] [Related]
11. Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I Long VP; Bonilla IM; Baine S; Glynn P; Kumar S; Schober K; Mowrey K; Weiss R; Lee NY; Mohler PJ; Györke S; Hund TJ; Fedorov VV; Carnes CA Life Sci; 2020 Jan; 240():117068. PubMed ID: 31751583 [TBL] [Abstract][Full Text] [Related]
13. The Partial AdeNosine A1 receptor agonist in patients with Chronic Heart failure and preserved Ejection fraction (PANACHE) trial. Bertero E; Maack C Cardiovasc Res; 2019 Jul; 115(8):e71-e73. PubMed ID: 31180465 [No Abstract] [Full Text] [Related]
14. INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. Mor M; Shalev A; Dror S; Pikovsky O; Beharier O; Moran A; Katz A; Etzion Y J Pharmacol Exp Ther; 2013 Jan; 344(1):59-67. PubMed ID: 23055540 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. Rueda P; Merlin J; Chimenti S; Feletou M; Paysant J; White PJ; Christopoulos A; Sexton PM; Summers RJ; Charman WN; May LT; Langmead CJ Front Pharmacol; 2021; 12():628060. PubMed ID: 33776771 [TBL] [Abstract][Full Text] [Related]